KAMADA » MEDIA » NEWS

NEWS


Kamada Reports Financial Results for Second Quarter and First Six Months of 2018

/ Aug. 7, 2018

Kamada announced financial results for the three and six months
ended June 30, 2018.

Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT

Press Release / Jul. 10, 2018

Kamada announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the development plan for its proposed pivotal Phase 3 study for its proprietary Inhaled Alpha-1 Antitrypsin therapy (Inhaled AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD).

50 years since the first use of Anti-D immunoglobulin

In The News: Kamada / Jul. 1, 2018

Since 1967, the lives of countless babies have been saved by the pioneering Rh Program - and to date, millions of doses of anti-D have been given to Rh negative women.

Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

Press Release / Jun. 4, 2018

The results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA).

Kamada Reports Financial Results for First Quarter of 2018

Press Release / May. 15, 2018

Kamada today announced financial results for the three months ended
March 31, 2018.

Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

Press Release / May. 8, 2018

KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches.

Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Apr. 24, 2018

Kamada announced that the company recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the proposed pivotal Phase 3 protocol for its proprietary Inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

Press Release / Feb. 7, 2018

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017.

Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Press Release / Jan. 8, 2018

The company announced interim results from the Company’s Phase 2 trial of intravenous Alpha-1 Antitrypsin (IV AAT) for the prevention of lung transplant rejection.

Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

Press Release / Jan. 4, 2018

Kamada announced a collaboration with the Mount Sinai Acute GvHD International Consortium (MAGIC) to conduct a proof-of-concept clinical trial assessing the safety and preliminary efficacy of Kamada’s Alpha- 1-Antitrypsin (AAT) as preemptive therapy for patients at high-risk for the development of steroidrefractory acute GvHD (SR-aGvHD).

out of 155 items.